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Background: This study addresses the yield and clinical impact of computed tomography (CT) 
imaging in otherwise asymptomatic patients with stage III melanoma metastatic to the regional 
nodes. 
Methods: The database from the University of Michigan Mutlidisciplinary Melanoma Clinic was 
reviewed and identified 127 asymptomatic patients with stage III melanoma (regional nodal disease) 
who received CT scans of the head, chest, abdomen, and/or pelvis. Scans were confirmed as true 
positive, false positive, and normal. 
Results: Four hundred twenty-six head and body CT scans were performed at the time of 
presentation of stage III disease. Twenty patients had a true-positive CT scan revealing unsuspected 
metastases. Fifteen patients had abnormal CT scans subsequently shown to be a benign process or 
second malignancy. The incidence of true-positive CT scans was not different between the groups 
of patients who had clinically apparent versus occult nodal disease. There was a significantly higher 
incidence of abdominal and pelvic metastatic sites identified by CT scan in patients with inguinal 
nodal disease compared with axillary or head and neck node-positive patients. 
Conclusions: The yield of detection of unsuspected metastases by CT scans in asymptomatic 
patients with stage III melanoma was not insignificant. Because patients with resected stage III 
disease are recommended to have adjuvant interferon-c~ for 1 year, CT staging plays an important 
role in identifying appropriate candidates for treatment. The toxicity of interferon-(x therapy is not 
insignificant. The value of routine CT in asymptomatic patients with nodal metastasis deserves 
further prospective study. 
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The prognosis of  patients with melanoma who present 
with lymph node metastases (AJCC clinical stage III: 
any T, N1 or N2, M0) is relatively poor, suggesting that 
most patients who undergo lymphadenectomy for stage 
III  disease have occult distant metastases at the time of 
initial diagnosis (1). Based on several reported series, the 
5-year survival rate for patients with stage III melanoma 
after lymphadenectomy ranges from 13 to 45%, with an 
average of  34% (2-6). Regardless of  the specific site, 
regional lymphadenectomy is a morbid p rocedure - -  
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associated with significant costs to patients and to soci- 
ety that fails to cure the majority of individuals with 
nodal involvement (6,7). Any technique capable of  iden- 
tifying patients with stage III  disease with clinically un- 
suspected distant melanoma metastasis, often obviating 
the need for lymphadenectomy and/or relatively toxic 
adjuvant interferon-o~ therapy, would be likely to have 
significant clinical value. 
Melanoma can metastasize to any organ. The most 
common sites of metastases are to skin, subcutaneous 
tissue, and lymph nodes, followed by visceral organs. 
Common visceral sites of metastases, in order of  decreas- 
ing frequency, are lung, liver, brain, bone, and gastroin- 
testinal tract (8-10). Cutaneous and subcutaneous metas- 
tases, as well as spread to lymphatic basins amenable to 
palpation (e.g., neck, axilla, and groin), can be readily 
detected by physical examination, but involvement of 
mediastinal, intraabdominal, and pelvic nodes cannot. 
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Likewise, most visceral metastases are initially asymp- 
tomatic and not detectable on physical examination. El- 
evation of the serum lactate dehydrogenase (LDH) level 
is generally thought to be the most sensitive serum 
marker of melanoma metastases, particularly to the liver, 
but is notorious for being of low sensitivity and speci- 
ficity. Chest radiography will detect most pulmonary me- 
tastases >1-2 cm, but will frequently miss smaller le- 
sions. 
Computed tomography (CT) scans of the head, chest, 
abdomen, and pelvis offer the potential to detect most 
metastatic sites of melanoma that would be missed by 
physical examination. True-positive scans identifying 
unsuspected melanoma metastasis alters clinical man- 
agement and is of significant clinical value. Unfortu- 
nately, these scans will also frequently identify clinically 
insignificant findings, such as pulmonary granulomas or 
hepatic cysts. These false-positive findings, moreover, 
often prompt significant patient anxiety as well as costly 
follow-up evaluations. The true value of using CT scans 
of the head and body in otherwise asymptomatic patients 
who present with lymph node metastasis is therefore a 
matter of significant interest in management of this dis- 
ease. During an l l -year  period, 127 asymptomatic pa- 
tients who presented with lymph node metastases (AJCC 
clinical stage III disease) were evaluated in the Univer- 
sity of Michigan Multidisciplinary Melanoma Clinic. As 
a part of their evaluation, patients underwent at least one 
CT scan of the head, chest, abdomen, or pelvis. We 
report the results of routine CT scanning in these pa- 
tients. 
PATIENTS AND METHODS 
The melanoma database (from the period 1984-1995) 
was queried to identify 127 asymptomatic patients who 
had melanoma metastatic to the regional lymph nodes 
and who had at least one staging CT scan within 2 
months of diagnosis. Patients with melanoma metastatic 
to the regional nodes with CT scans obtained beyond 2 
months of diagnosis and those with signs or symptoms of 
distant disease before staging CT scans were excluded 
from chart review and analysis. The charts of these 127 
patients with stage III melanoma metastatic to the re- 
gional lymph nodes seen in the University of Michigan 
Multidisciplinary Melanoma Clinic were retrospectively 
reviewed. The number and location of CT scans were 
obtained at the discretion of the attending physician. In 
total, 426 CT scans were performed in these 127 patients 
of the following locations: head (99), chest (117), abdo- 
men (121), and pelvis (89). Chest radiographs and liver 
function studies were not routinely ordered because most 
patients had CT scans of the chest and abdomen as part 
of the staging work-up. 
CT scans were considered positive whenever an ab- 
normality was reported by the radiologist as suspect for 
metastasis or whenever an indeterminate abnormality re- 
quired further diagnostic evaluation or follow-up studies 
to define its nature. A positive scan was considered a true 
positive when confirmed to represent melanoma by bi- 
opsy or when subsequent follow-up documented clear- 
cut progression in the size and/or number of lesions con- 
sistent with metastatic melanoma. A positive scan was 
considered a false positive when found to represent a 
benign process or malignant, nonmelanoma lesion by 
biopsy, when subsequent follow-up documented resolu- 
tion or stability, or when subsequent diagnostic studies 
determined the lesion to be consistent with a benign pro- 
cess. 
RESULTS 
The clinical characteristics of the 127 patients with 
regional nodal metastases are listed in Table 1. Twenty- 
eight patients were diagnosed with microscopic disease 
at elective lymph node dissection (ELND). The remain- 
ing 99 patients had palpable disease diagnosed by fine- 
needle aspirate, open biopsy, or therapeutic lymph :node 
dissection. Four hundred twenty-six total scans were per- 
formed in these 127 patients (3.4 scans/patient). In total, 
35 (27%) of 127 patients had abnormal CT scans in 
which there were findings suspicious for metastases. 
Twenty patients (16% of total, 57% of suspect scans) 
were found, on subsequent workup, to have true positive 
findings. Fifteen patients (12% of total, 43% of suspect 
scans) were found to have false positive findings. Nine- 
teen of the patients with true positive CT scans had them 
performed within 1 month of diagnosis. The remaining 
patient was studied within 2 months of diagnosis. Inter- 
estingly, 6 (21%) of 28 patients diagnosed with micro- 
scopic disease at ELND had true positive findings, 
whereas 14 (14%) of 99 patients with palpable disease 
had true positive findings. Five (18%) of 28 patients with 
microscopic disease and 10 (10%) of 99 patients with 
palpable disease had false positive findings. 
In this group of 20 patients with true positive scans, 
significant findings for silent distant metastases were 
found in 6 head CT scans, 11 chest, 12 abdomen, and 4 
pelvis (Table 2). Multiple positive findings were found in 
several scans. Of the 11 patients with true positive chest 
CT scans, 9 scans showed lung metastases and 4 new 
nodal metastases (1 axillary, 3 mediastinal, paratracheal, 
subcarinal). Confirmation of diagnosis was made by bi- 
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TABLE 1. Clinical characteristics of 127 patients staged 
with computed tomography scanning for stage III 
(nodal) disease 







Location of regional nodal disease ~ 
Axillary 62 




Location of primary melanoma 
Head & neck 31 
Upper extremity 15 
Lower extremity 25 
Trunk 42 
Unknown 14 
Method of diagnosis before staging 
FNA 43 
Open biopsy 39 
ELND 28 
Open biopsy-ELND (same time) 16 
Clinical mass 1 
No. of  initial scans performed on patient 





ELND, elective lymph node dissection. 
Three patients had two different simultaneous sites of nodal me- 
tastasis from a primary lesion located on the trunk. 
opsy in three cases and progression of disease in the 
remaining cases. In those 11 patients with true positive 
chest CT scan findings, a chest radiograph was not or- 
dered in 5, was negative in 3, and was positive in 3. Of 
the six true positive CT scans of the head, five showed 
brain metastases, and one showed a cervical spine me- 
tastasis. Confilanation of metastases was made by biopsy 
in two patients and progression of disease in four. 
Of the 12 patients with true positive abdomen CT 
scans, 6 scans showed metastases to the liver, 3 to the 
spleen, 1 to the adrenal gland, and 6 to visceral nodes 
(retroperitoneal, periaortic, or mesenteric), 1 to the spine, 
and 2 to subcutaneous or extrapefitoneal soft tissues. 
Diagnosis was confirmed by clear-cut progression of dis- 
ease in all cases. Of the six patients with liver metastasis, 
serum LDH was elevated in three and normal in three. 
True positive abdominal CT scans yielded extrahepatic 
(68%) metastasis more often than hepatic (32%) metas- 
tasis. Of the four true positive CT scans of the pelvis, all 
showed enlarged (or abnormal) retroperitoneal or peri- 
aortic nodes. The diagnosis was similarly confirmed by 
progression of disease in all cases. All four patients had 
the primary melanoma located on the lower extremity. In 
summary, 6 (6%) of 99 CT scans of the head, 11 (9%) of 
t17 chest, 12 (10%) of 121 abdomen, and 4 (4%) of 89 
pelvis demonstrated unknown distant metastases in our 
series (Table 3). Of note, pelvic CT scans demonstrated 
metastases in 4 (16%) of 25 patients with the primary 
melanoma on the lower extremity. 
Fifteen (12%) of 127 patients had false positive CT 
scans that showed abnormalities considered suspect for 
metastases that were shown to be unrelated to melanoma 
by subsequent studies (Table 4). Of these, 9 abnormal 
CT scans of the chest were found. Four showed a lung 
nodule and one an axillary node that resolved or re- 
mained stable with subsequent follow-up studies. One 
showed a paratracheal mass thought to be thyroid, one a 
left breast mass confirmed to be a benign cyst by biopsy, 
one a precarinal node negative for metastases by biopsy, 
and one lytic fourth/rib lesion revealing an undiagnosed 
multiple myeloma by biopsy. Of the eight abnormal ab- 
dominal CT scans, five revealed benign lesions: liver 
cysts by biopsy in two and, based on follow-up scans in 
three, one a liver mass negative for melanoma after two 
biopsies, one adrenal adenoma by biopsy, and one con- 
sistent with a hemangioma based oll follow-up scans. 
Two of these 15 patients had two abnormal scans (chest 
and abdomen) accounting for the total of 17 abnormal 
scans. No false positives were found by CT scans of the 
head and pelvis (see Table 3). 
Stratification of the data with respect to location of 
regional disease found a higher percentage of true posi- 
tive findings in patients with axillary and inguinal me- 
tastasis compared with those for head and neck (Table 5). 
Seven (25%) of 28 patients with inguinal metastasis were 
found to have true positive scans most commonly of the 
abdomen (19%), pelvis (15%), and chest (13%). Twelve 
(19%) of 64 patients with axillary metastasis were found 
to have true positive scans, most commonly of the chest 
(15%), abdomen (12%), and head (9%). Three (8%) of 
38 head and neck and supraclavicular metastasis were 
found to have true positive scans, most commonly of the 
chest (5%). 
DISCUSSION 
Numerous investigators have shown that CT scanning 
of the head and body and other diagnostic radionuclide 
testing is neither usefut nor cost effective in detecting 
silent metastases in patients with localized (AJCC stage 
I and II) melanoma (11,12). This has been our experience 
as well. 
Khansur et al. (12) reported 54 patients with nodal 
metastases and 28 with local/regional recurrences. These 
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TABLE 2. Computed tomography scan findings in 20 patients who presented with abnormal scans detecting silent 
d i s tan t  m e t a s t a s e s  
Location of Microscopic 
Pt regional nodal vs. palpable Radiologic findings 
no. metastasis disease by CT scan Comments 
1 Inguinal Palpable (A/P) Paraanrfic, common and common external Repeat (A/P) CT after 3 mo showed proga'essive 
iliac, obtmator nodes increase in size and number of nodes. Patient 
died of widespread disease. 
2 Axillary and Palpable Repeat chest CT @ 4 mo showed progression in 
supraclavicular size and number of left axillary nodes, pleural, 
and chest wail metastases; DOD, initial CXR 
negative. CXR positive at 4 too. 
3 Axillary Patient developed widespread metastases, mental 
status changes; DOD I mo after initial CTs. 
LDH elevated. 





6 Inguinal and axillary Palpable 
7 Axillary Microscopic 
8 AxiUary Palpable 
9 Axillary Palpable 
10 AxiUary Palpable 
11 Axillary Palpable 
12 Axillary Microscopic 
13 Axillary Microscopic 
14 Inguinal Palpable 
15 Inguinal Microscopic 
16 Inguinal Palpable 
17 Head and neck Palpable 
18 Axillary Palpable 
19 Inguinal Palpable 
20 Head and neck Palpable 
(C) 1.5-cm subclinical node and other smaller 
nodes left axilla 
(H) Multiple brain metastases 
(A) Multiple liver/spleen metastases 
(A/P) Extensive paraaortic, retropefitoneal, 
external iliac nodes 
(A) Multiple lesions, R lobe liver 
(C) 4 small 5-ram lung nodules, mediastinal, 
paratracheal, subcarinal nodes 
(P) External iliac nodes bilateral 
(C) Multiple bilateral pulmonary nodides, 
subcarinal, retrocrural, gastrohepatic nodes 
(H) Multiple 1-2-ram areas of enhancement 
consistent with brain metastases 
(A) MultipIe liver, spleen, abdominal walt 
nodules 
(A) Extensive liver/spleen metastases, necrotic 
pefipancreatic adenopathy, multiple 
omental/meseutefic/retropefitoneal nodules, 
and multiple vertebral body iucencies. 
(C) Multiple lung nodules. 
(H) Multiple brain metastases. 
(C) Enlarged precarinal node. 
(A) Aortocaval, retrocmral adenopathy 
(C) 25-50 <l-l .5-cm lung nodules 
(A) Multiple low-attenuation liver lesions 
(C) Multiple lung nodules 
(A) Paraaortic nodes 
(H) Frontal brain metastases 
(A) 2-cm adrenal mass 
(A/P) Paraaortic/retrocaval/retroaortic nodes 
(C) Multiple lung nodules 
(A) Multiple liver nodules, 3-4-cm soft-tissue 
mass at the ileocecal valve 
(C) Multiple lung nodules 
(C) Lung nodule 
(C) 2 small lung nodules 
(H) Cervical spine (C2) destructive process 
(It) 1.7-cm mass lesion choroid plexus 
Repeat CT (A) 2, 4, and 8 mos; progression in 
size and number of metastases, spleen 
metastases. Widespread metastases in head, 
chest, abdomen 8 mo after initial CTs. Initial 
LDH normal, elevated at 1 mo. 
Repeat CT (C) 1, 3, 5, 7, 9 mo showed 
progression of disease, Initial CXR negative, 
Biopsy of lung nodules positive for melanoma. 
Repeat CT (A) after 1 mo showed rapid 
progression of disease. LDH elevated. 
Repeat CT (A,C) 2 and 3 mo showed progression 
in size and number of metastases. LDH 
elevated. Initial CXR negative. 
Marked progression of widespread metastatic 
disease with increase in thoracic, abdominal, 
retroperitoneaI, and mesenteric 
lymphadenopathy on repeat CT scans at 10 
months. 
Progression of metastatic melanoma to multiple 
organs. Lung biopsy positive for melanoma. 
Repeat CT (A) and CXR at 3 mo showed 
progression of metastases to lung/liver. Patient 
developed widespread melanoma metastases 
over 8 too. Initial LDH normal, elevated at 7 
mo. 
Rapid clinical and CXR progression of metastatic 
melanoma. DOD 6 mo after stage III 
diagnosis. Initial CXR positive, 
Patient developed widespread metastases to the 
lungs, adrenal glands, kidneys, subcutaneous 
fat, and peritoneal cavity over I yr. 
Repeat MR1 (A) at 1 mo showed progression of 
disease. 
Repeat CT (C/A) showed progression of size and 
number of lung/liver metastases. Initial LDH 
normal, not repeated. Initial CXR positive. 
Biopsy of lung nodule positive for metastic 
melanoma. 
Biopsy positive for melanoma. 
Biopsy of cervical spine positive for melanoma. 
Repeat CT at 2 mos showed progression of 
lung metastases. Patient alive 1.5 yrs after 
diagnosis of metastases. 
Biopsy positive for melanoma brain metastases. 
Patient alive with disease 3 yr after diagnosis 
of brain metastases. 
(H), head CT; (C), chest CT; (A), abdomen CT; (P), pelvis CT; DOD, dead of disease; LDH, lactate dehydrogenase; CXR, chest radiograph. 
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TABLE 3. Summary of computed tomography (CT) 
scan findings 
True False 
CT scan Total no. positive positive 
Head 99 6 (6%) 0 
Chest 117 tl (9%) 9 (8%) 
Abdomen 121 12 (10%) 8 (7%) 
Pelvis 89 4 (4%) 0 
patients underwent some combination of the following 
evaluations: radionuclide brain, bone, and liver scan; CT 
scan of the head; and upper gastrointestinal series with 
small-bowel follow-through. All patients in their series 
had a chest radiograph, liver function tests, and serum 
LDH. Seven asymptomatic patients had lung metastases 
by chest radiography. Five abnormal radionuclide scans 
detected metastases in the brain (one), bone (one), gas- 
trointestinal tract (one), and spleen (two) in asymptom- 
atic patients with normal liver function tests. The authors 
did not state whether multiple metastases in the same 
patient were found with abnormal chest radiographs and 
radionuclide scans. Still, these data suggest that a chest 
radiograph and a battery of radionuclide scans may de- 
tect metastases in at least 10% of asymptomatic stage III 
patients. 
Roth et al. (13) and Thomas et al. (14) reported on the 
value of brain, bone, and liver-spleen nuclear medicine 
scans in 58 and 48 patients, respectively, with stage III 
disease. Only one patient had an abnormal scan detecting 
distant metastases. There were a significant number of 
false positive scan results in these series. Therefore, it 
was concluded that radionuclide scanning was not indi- 
cated for screening of patients with stage III disease. 
The value of head and body CT imaging in patients 
who present with nodal metastases (AJCC stage III) has 
been evaluated in one large series (15). Buzaid et al. (15) 
analyzed 89 asymptomatic patients with stage III local- 
regional melanoma who had both a normal chest radio- 
graph and normal serum LDH level. Sixty-six patients 
had purely nodal disease. The remaining 23 patients had 
in-transit/satellite or local recurrence with (8) or without 
(15) nodal disease. A total of 304 CT scans were per- 
formed in those 89 patients in the following locations: 
head (57), neck (t6), chest (82), abdomen (86), and pel- 
vis (63). True positive findings were found in six patients 
(7%). True positive findings were noted in one chest and 
five abdomen or pelvis scans. Pelvic CT scans showed 
metastases in 4 of 28 (t4%) patients with melanoma 
below the waist. False positive findings were found in 20 
of 89 (22%) patients. No CT scans of the brain showed 
CNS metastases, although an asymptomatic skull metas- 
tasis was found in one patient. Buzaid et at. (15) con- 
cluded that a CT scan of the chest adds little, to the 
information obtained from a chest radiograph and there- 
fore, may not be indicated. Additionally, an elevated se- 
rum LDH level may indicate metastatic disease, but the 
specificity and sensitivity of LDH levels were low. How- 
ever, an elevated LDH level, particularly in the postop- 
erative period, may indicate distant metastasis. 
Our study group contained approximately two times 
the number of pure node positive patients reported by 
Buzaid et al. Our group was not consistently evaluated 
with routine chest radiographs or serum LDH levels be- 
cause CT scans of the chest and abdomen were routinely 
performed. In the 11 patients with positive CT scans of 
the chest, a chest radiograph was not obtained in 5, nega- 
tive in 3, and positive in 3. In our series, abdominal CT 
scans were more likely to yield nonhepatic (68%) than 
hepatic (32%) metastases. All false positive scan results 
were found in either the chest (9) or abdomen (8). In fact, 
the frequency of a false positive versus true positive scan 
in the chest and abdomen were about equal. Still, the 
false positive findings often served as a useful baseline 
for comparison in this high-risk group of patients with 
stage III melanoma. Of note, no false positive CT scans 
were found in the head and pelvis. 
The most striking significant difference between our 
series and the series reported by Buzaid et al. (15) is the 
result of CT scanning of the head. Although Buzaid et al. 
reported no brain metastases and only 1 skull metastasis 
in 57 head CT scans, we found 5 brain metastases and 1 
spinal metastasis in 99 studies. Melanoma has a clear 
predilection for metastases to the CNS, one of the most 
ominous features of the disease. Our study contained 1.4 
times the number of total patients and nearly two times 
the number of pure node positive patients and number of 
CT scans of the head compared with the series by Buzaid 
et al. The gender, median age, and type of lymph node 
dissection (elective versus theraputic) were similar be- 
tween the two studies. 
Documentation of CNS involvement has an impact on 
the management of the patient, given the fact that surgi- 
cal and/or medical control of melanoma outside the CNS, 
although usually palliative, continues to improve. Surgi- 
cal resection or stereotactic radiosurgical intervention for 
CNS melanoma, although not curative, may" increase sur- 
vival in patients with little morbidity and mortality even 
in the presence of extracranial metastases (16,17). Addi- 
tionally, the presence of CNS disease usually precludes 
patient eligibility for treatments such as interleukin-2, or 
innovative protocols such as gene therapy, adoptive im- 
munotherapy, and gene-modified adoptive immuno- 
therapy (7,18-22). 
Interestingly, our series demonstrated a similar true 
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T A B L E  4. Radiologic findings in 15 patients who presented with abnormal scans at the time of diagnosis found to be 
unrelated to melanoma 
Pt 
no. 
Location of Microscopic 
regional nodal vs. palpable Radiologic findings 
metastasis disease by CT scan Commems 
1 Head and neck Microscopic (C) Lung noduIe 
2 Head and neck Palpable (C) 2 small Iung nodules R L lobe 
3 Axillary Palpable (A) Adrenal mass 
4 Axillary Palpable (A) Liver mass 
5 Axillary Microscopic (C) Axillary node 
6 Axillary Palpable (C) Precarinal node 
7 Inguinal Microscopic (A) Liver nodule 
8 Inguinal Palpable (C) Breast density 
9 Head and neck Microscopic (C) Fourth rib lesion 
10 AxillaLw Microscopic (C) Paratracheal mass C/W 
retrosternal thyroid 
(A) Liver mass 
11 Axillary Palpable (A) Liver lesion 
12 Inguinal Palpable (A) Tiny liver lesion 
13 Axillary Palpable (C) 4-mm lung nodule 
(A) <l-cm liver lesion 
14 Head and neck Palpable (A) 4-cm liver mass 
15 Inguinal Palpable (C) SingIe 7 x 5-mm nodule R 
perihilar region 
Repeat CT (C) at 3 mo, CXR at 5 yrs unchanged. 
Repeat CXR negative at 1 yr. 
Biopsy--adenoma. 
Repeat MRI consistent with benign cysts. Repeat 
CT (A) at 5 mo unchanged. 
Repeat CT (C) at 2 mos: node resolved. 
Biopsy negative for melanoma. 
Biopsy x 2 negative for melanoma. 
biopsy showed benign cyst. 
Biopsy positive for multiple myeloma. 
Repeat CT (C/A) at 3 and 12 mo unchanged; liver 
mass CJW hemangioma. 
Biopsy showed benign cyst. 
Repeat CT (A) at 6 and 24 mo unchanged. 
Repeat CT (C/A) at 3 mo unchanged. Liver lesion 
consistent with benign cyst. 
Biopsy showed benign cyst. 
Repeat CT (C) at 6 too, nodule resolved. 
MRI, magnetic resonance imaging. For other abbreviations, see Table 2. 
positive rate for patients with microscopic disease diag- 
nosed by ELND versus patients with palpable disease. 
This finding may reflect our close follow-up and teach- 
ing of the importance of self lymph node examination to 
the patient resulting in early detection of palpable nodal 
disease. The similar number of true positive scans in the 
patients with microscopic disease and early paIpable dis- 
ease is consistent with two prospective randomized trials 
reporting no improvement in survival in patients treated 
T A B L E  5. Computed tomography (CT) scan findings with 
respect to location of regional metastasis 
Location of 
positive CT scans 
No. of and percentage of 
Location of patients with total scans 
regional nodal No. of true positive positive for 
metastasis patients ~ scans each location 
Axilla/epitrochlear 64 12 (19%) 
Inguinal 28 7 (25%) 
Head/neck 38 3 (8%) 
Supraclavicular 
4 Head (9%) 
8 Chest (15%) 
7 Abdomen (12%) 
1 Pelvis (3%) 
1 Head (6%) 
3 Chest (13%) 
5 Abdomen (19%) 
4 Pelvis (15%) 
1 Head (3%) 
2 Chest (5%) 
0 Abdomen (0%) 
0 Pelvis (0%) 
Three patients had more than one location of metastasis simulta- 
neously with the primary lesion located on the trunk in an area of 
multiple primary nodal drainage areas. 
with ELND versus a watch and wait approach, with 
therapeutic lymphadenectomy performed only when 
there are signs of nodal metastasis (23,24). With the 
recent data reporting the modest efficacy of adjuvant 
therapy with interferon-(x for patients with stage III 
melanoma, the new technique of lymphatic mapping and 
sentinal node biopsy has gained popularity and has re- 
placed ELND for nodal staging (25-29). In this setting, 
the finding of stage IV disease documented with CT 
scans would alter clinical management by both altering 
systemic therapy and avoiding a relatively toxic regimen 
of adjuvant interferon-a (30), and reserving palliative 
lymphadenectomy only for those patients who are symp- 
tomatic from their nodal disease. 
On the basis of the results from our series, the follow- 
ing conclusions can be drawn regarding head and body 
CT scanning for patients with metastatic melanoma to 
the regional nodes. First, false positive findings are al- 
most as COl~non as true positive findings. Therefore, 
follow-up studies noting obvious progression of disease 
or preferably a tissue diagnosis are often necessary to 
confirm the presence of metastatic melanoma. Second, 
CT scanning or magnetic resonance imaging of the head 
rarely detects brain metastases. Although the yield is 
low, the impact of positive findings may be significant. 
Third, CT scanning of the pelvis is indicated only for 
patients in whom the primary melanoma lymphatics 
drain to the pelvic nodal basin. Fourth, abdominal CT 
scanning is recommended and is more likely to demon- 
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strate extrahepatic metastatic disease, which may not be 
detected by an elevated serum LDH level. Of note, three 
(50%) of six patients with liver metastasis had a concur- 
rent normal LDH level. Finally, a small number of pul- 
monary metastases may be detected by chest CT despite 
a negative chest radiograph. Our retrospective analysis 
does not permit a definitive conclusion to be drawn re- 
garding the utility of chest radiograph versus chest CT 
scanning in patients with stage III melanoma, because a 
chest radiograph was not routinely obtained. However, 
of note, 3 (27%) of 11 patients with a true positive CT 
scan of the chest had a concurrent normal chest radio- 
graph. 
In conclusion, routine head and body CT scanning in 
asymptomatic patients with melanoma metastatic to the 
regional nodes infrequently identifies unsuspected meta- 
static disease. However, unsuspected metastatic disease 
may alter the subsequent clinical management in these 
patients. In our cost-conscious age, the benefit of head 
and body staging CT must be weighed against the cost. 
Based on our data, prospective evaluation and cost/ 
outcome analyses of routine head and body staging CT 
scanning for patients with melanoma metastatic to the 
regional nodes deserves further study. 
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